Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg To Be Presented at the 67th American Society of Hematology Annual Meeting and Exposition Life Science Investing
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update Life Science Investing
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program Life Science Investing
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock Life Science Investing
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules Life Science Investing
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates Life Science Investing
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease Conference Life Science Investing
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December Life Science Investing
